You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2025

Profile for Poland Patent: 210697


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Poland Patent: 210697

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,332,472 Oct 17, 2025 Aurinia LUPKYNIS voclosporin
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Poland Drug Patent PL210697

Last updated: July 28, 2025


Introduction

Patent PL210697 pertains to a pharmaceutical invention registered in Poland. Understanding its scope, claims, and the landscape surrounding it is crucial for stakeholders including generics manufacturers, research entities, and licensing firms. This analysis offers an in-depth review of the patent’s legal scope, its claims, and positioning within the broader patent environment to inform strategic decision-making.


Patent Overview

Patent PL210697 was granted in Poland, covering novel pharmaceutical compositions or methods linked to a specific drug candidate. While the exact title and inventor details require consulting the Polish Patent Office (PPTO) database, typical content involves a possibility of patenting active ingredients, formulations, or methods of synthesis.


Scope of the Patent

The scope of a patent defines the boundaries of the legal protection conferred. In PL210697, the scope encompasses:

  • Novelty and Inventive Step: The patent protects an invention that is new and involves an inventive step over existing technologies, aligning with Polish Patent Law [1].
  • Subject Matter: Likely focuses on pharmaceutical compounds, formulations, or methods of manufacturing that demonstrate unexpected clinical benefits or enhanced stability.
  • Geographical Limitation: As a national patent, protections are confined to Poland unless extended via filings in other jurisdictions through the Patent Cooperation Treaty (PCT) or direct national filings.

The scope is detailed in the claims section, which explicitly spells out the protected features and exclusions. The scope’s breadth depends on how comprehensively the claims are drafted, balancing broad coverage against enforceability.


Claims Analysis

Type and Nature of Claims

Patent claims are structured as either independent or dependent. Independent claims define the broadest scope, with dependent claims narrowing or specific embodiments.

Typical Claims in PL210697 may include:

  • Product Claims: Covering the active pharmaceutical ingredient (API) or compositions containing the API.
  • Method Claims: Details on specific processes for synthesizing the API, formulation techniques, or administration methods.
  • Use Claims: Medicines indicated for particular indications or patient populations.

Claim Language and Clarity

Clear, precise claim language minimizes infringement ambiguities. For example, claims might specify:

  • Chemical Structure: Specific molecular formulas, stereochemistry, or derivatives.
  • Formulation Parameters: Particle size, excipient types, or release profiles.
  • Method Steps: Conditions such as temperature, pH, catalysts, or purification steps.

Scope of the Claims

  • Broad Claims: Cover extensive variants of a compound or method, offering robust protection but risk of invalidity if too encompassing.
  • Narrow Claims: Target specific embodiments, easier to defend but more susceptible to design-around strategies.

For PL210697, the claims likely straddle a balance, aiming to cover innovative aspects while avoiding prior art obstacles.


Patent Landscape Context

Global Patent Environment

The patent landscape around pharmaceuticals involves multiple layers:

  • International Patents: Applications filed via PCT or in key jurisdictions like the EU, US, and China to secure broader protection.
  • EPO and EU Patents: Given Poland’s participation in the European Patent Convention, similar patent rights could be pursued via EPO routes, potentially encompassing multiple member states.

Prior Art and Patent Family

Analysis reveals whether the invention overlaps with existing patents or technologies. Patent family members or cited references in the application provide insight into the inventive distance and potential freedom-to-operate (FTO) concerns.

Competitive Landscape

  • Active Patent Holders: Major pharmaceutical players may hold similar patents, potentially blocking or licensing.
  • Patent Expirations and Deadlines: Timing affects market exclusivity and generic entry strategies.

Legal Status and Challenges

The patent’s enforceability in Poland hinges on:

  • Grant Validity: Confirmed via official status records.
  • Oppositions or Litigation: Possible post-grant challenges from competitors.
  • Maintenance and Annuities: Regular payments ensure ongoing protection.

Strategic Implications

  • For Innovators: Confirming if PL210697’s claims cover core innovations or can be extended to other jurisdictions.
  • For Generics: Assessing the patent’s scope to evaluate patent expiry or design-around opportunities.
  • For Licensors: Determining licensing potential based on the patent's enforceability and territorial scope.

Conclusion

Patent PL210697 exemplifies a targeted pharmaceutical patent with claims likely centered on a novel API, formulation, or method. Its strategic value resides in the breadth and enforceability of these claims against competitors and within the global patent landscape. Continuous monitoring of legal status, claim amendments, and similar patents in the domain is essential for positioning in the Polish and broader European markets.


Key Takeaways

  • The scope of PL210697 hinges on precise claim drafting, balancing broad protective claims with enforceability.
  • Analyzing patent claims reveals the invention's core technical features and potential limitations.
  • The patent landscape impacts market exclusivity, licensing opportunities, and potential design-arounds.
  • Ongoing legal status checks and patent family analyses are vital to maintaining competitive advantage.
  • Strategic players must consider international filings to extend protection beyond Poland while respecting existing patents to avoid infringement.

Frequently Asked Questions

1. How does Poland’s patent law influence the scope of pharmaceutical patents like PL210697?
Polish patent law requires that claims be clear, novel, and involve an inventive step. This influences claim drafting to ensure valid scope—broad enough to protect innovation, yet specific enough to withstand challenges.

2. Can the scope of PL210697 be extended to other countries?
Yes. The patent applicant can file corresponding patent applications via the PCT route or directly in other jurisdictions, subject to regional laws and patentability criteria.

3. What strategies can competitors use if PL210697’s claims are broad?
Competitors may pursue design-around patents, challenge validity via patents opposition procedures, or develop alternative formulations outside the scope of the claims.

4. How does claim dependency influence patent strength?
Dependent claims narrow the invention but strengthen patent defensibility by covering specific embodiments, while independent claims define the broadest scope that can be attacked or defended.

5. What factors determine the enforceability of PL210697 in Poland?
Enforceability depends on the patent’s legal standing, validity, claim clarity, and absence of successful opposition or invalidity proceedings.


References

[1] Polish Patent Law, Act of 30 June 2000 – Law on Industrial Property, as amended.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.